Stifel downgrades BioMarin stock rating to Hold amid Voxzogo concerns

Stifel downgraded BioMarin Pharmaceutical Inc. (BMRN) to Hold from Buy, reducing its price target to $61, citing mounting competitive threats to its Voxzogo treatment and underlying growth weakness, a sentiment echoed by other analysts who also lowered their price targets. The company reported Q3 2025 revenue and EPS slightly below consensus, with Voxzogo sales missing expectations by 6%, although BioMarin reaffirmed its full-year 2025 Voxzogo guidance and noted stronger performance in its base business. Despite a positive FDA development for PALYNZIQ, persistent competitive concerns are expected to limit near-term stock upside for BMRN.

Analysis

Stifel downgraded BioMarin Pharmaceutical Inc. (BMRN) to Hold from Buy, reducing its price target to $61 from $73, primarily due to mounting competitive threats to its Voxzogo treatment. Key opinion leader checks revealed concerning feedback, and Voxzogo's underlying growth trends were already weak prior to competitive pressures emerging. This creates a challenging outlook for the drug's future performance.

BioMarin reported Q3 2025 total revenue of $776 million, slightly missing consensus estimates of $782 million, with Voxzogo sales approximately 6% below expectations. Despite reaffirming its fiscal year 2025 Voxzogo guidance, concerns persist regarding competition from Transcon-CNP or BBIO’s infigratinib, which analysts believe could limit stock upside even with successful trial outcomes for Voxzogo.

While the company's base business showed stronger-than-anticipated performance and the FDA accepted a Priority Review for PALYNZIQ's expanded use, the overall sentiment remains bearish. Multiple analysts, including Bernstein, Truist, RBC Capital, and H.C. Wainwright, have lowered their price targets, largely citing competitive pressures on Voxzogo. This collective adjustment underscores the market's concern over the company's key growth driver.

Key Decisions for Investors

• Investors should closely monitor the competitive landscape for Voxzogo, particularly developments from Transcon-CNP and BBIO’s infigratinib, as these pose significant overhangs on BMRN's growth prospects.
• Despite reaffirmed FY2025 Voxzogo guidance, investors should scrutinize future quarterly reports for actual sales performance against expectations, especially given the Q3 2025 miss and underlying weakness.
• While Voxzogo faces headwinds, investors should assess the potential impact of the PALYNZIQ expansion and other pipeline catalysts like DMD data or intellectual property outcomes, which could offer alternative drivers for BMRN's valuation.